Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits
MD Glantz, JC Anthony, PA Berglund, L Degenhardt, L Dierker, A Kalaydjian, KR Merikangas, AM Ruscio, J Swendsens, RC Kessler
Psychological Medicine | CAMBRIDGE UNIV PRESS | Published : 2009
Awarded by FOGARTY INTERNATIONAL CENTER
Awarded by NATIONAL INSTITUTE OF MENTAL HEALTH
Awarded by NATIONAL INSTITUTE ON DRUG ABUSE
Professor Kessler has been a consultant for GlaxoSmithKline Inc., Pfizer Inc., Wyeth-Ayerst, SanofiAventis, Kaiser Permanente, and Shire Pharmaceuticals; has served on advisory boards for Eli Lilly & Company and Wyeth-Ayerst; and has had research support for his epidemiological studies from Eli Lilly & Company, Pfizer Inc., Ortho-McNeil Pharmaceuticals Inc., and Bristol-Myers Squibb.